BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, November 12, 2024
Breaking News: Best of BioWorld Science: Q3
See today's BioWorld Science
Home
» University of Miami identifies new vasopressin V1A receptor antagonists
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Endocrine/metabolic
University of Miami identifies new vasopressin V1A receptor antagonists
Oct. 11, 2024
No Comments
University of Miami has patented new vasopressin V1A receptor antagonists reported to be useful for the treatment of osteoporosis, Paget disease and cancer.
BioWorld Science
Endocrine/metabolic
Patents